Literature DB >> 6541026

Diurnal variation in blood 17-hydroxyprogesterone concentrations in untreated congenital adrenal hyperplasia.

J Sólyom.   

Abstract

Blood spot 17-hydroxyprogesterone concentrations were measured serially over 24 hours in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency before they started treatment with glucocorticoids, and the development of diurnal rhythm in pituitary-adrenal activity was studied. Five infants aged 2 to 26 days showed an intradiem variation of 17-hydroxyprogesterone concentrations within the diagnostic range but without a characteristic diurnal pattern. Blood spot 17-hydroxyprogesterone values in a further eight patients aged 3 months to 6.5 years showed a diurnal rhythm, with high concentrations in the morning and a nadir in the evening. The results suggest that a diurnal rhythm in pituitary-adrenal activity may develop as early as the third month of life in those infants with an increased endogenous concentration of adrenocorticotrophic hormone.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6541026      PMCID: PMC1628610          DOI: 10.1136/adc.59.8.743

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  18 in total

1.  Pituitary-adrenal activity in untreated congenital adrenal hyperplasia.

Authors:  D K Fukushima; J W Finkelstein; K Yoshida; R M Boyar; L Hellman
Journal:  J Clin Endocrinol Metab       Date:  1975-01       Impact factor: 5.958

2.  The effect of different treatment regimens on hormonal profiles in congenital adrenal hyperplasia.

Authors:  R Smith; R A Donald; E A Espiner; C Glatthaar; G Abbott; M Scandrett
Journal:  J Clin Endocrinol Metab       Date:  1980-08       Impact factor: 5.958

3.  Microfilter paper method for 17 alpha-hydroxyprogesterone radioimmunoassay: its application for rapid screening for congenital adrenal hyperplasia.

Authors:  S Pang; J Hotchkiss; A L Drash; L S Levine; M I New
Journal:  J Clin Endocrinol Metab       Date:  1977-11       Impact factor: 5.958

4.  Diurnal variation of plasma 17-hydroxycorticosteroids in children.

Authors:  R C Franks
Journal:  J Clin Endocrinol Metab       Date:  1967-01       Impact factor: 5.958

5.  Circadian variation in plasma 17-hydroxyprogesterone in patients with congenital adrenal hyperplasia.

Authors:  S M Atherden; N D Barnes; D B Grant
Journal:  Arch Dis Child       Date:  1972-08       Impact factor: 3.791

6.  Neonatal screening for congenital adrenal hyperplasia.

Authors:  E Cacciari; A Balsamo; A Cassio; S Piazzi; F Bernardi; S Salardi; A Cicognani; P Pirazzoli; F Zappulla; M Capelli
Journal:  Arch Dis Child       Date:  1983-10       Impact factor: 3.791

7.  [Andrenogenital syndrome (author's transl)].

Authors:  E Nieschlag; H Wenner; H Breu; E J Wickings; G Schellong
Journal:  Dtsch Med Wochenschr       Date:  1980-04-25       Impact factor: 0.628

8.  The application of a serum 17OH-progesterone radioimmunoassay to the diagnosis and management of congenital adrenal hyperplasia.

Authors:  I A Hughes; J S Winter
Journal:  J Pediatr       Date:  1976-05       Impact factor: 4.406

9.  Hormonal and clinical responses to prednisone treatment in adolescents with congenital adrenal hyperplasia.

Authors:  W B Zipf; G E Bacon; R P Kelch
Journal:  Horm Res       Date:  1980

10.  Effect of cortisol treatment on hormonal relationships in congenital adrenal hyperplasia.

Authors:  G E Bacon; M L Spencer; R P Kelch
Journal:  Clin Endocrinol (Oxf)       Date:  1977-02       Impact factor: 3.478

View more
  7 in total

Review 1.  An update on male infertility and intratesticular testosterone-insight into novel serum biomarkers.

Authors:  Karim Sidhom; Kapilan Panchendrabose; Uday Mann; Premal Patel
Journal:  Int J Impot Res       Date:  2022-01-06       Impact factor: 2.896

2.  Duration of suppression of adrenal steroids after glucocorticoid administration.

Authors:  John S Fuqua; Deborah Rotenstein; Peter A Lee
Journal:  Int J Pediatr Endocrinol       Date:  2010-03-31

3.  170H-progesterone rhythms in congenital adrenal hyperplasia.

Authors:  M C Young; J A Robinson; G F Read; D Riad-Fahmy; I A Hughes
Journal:  Arch Dis Child       Date:  1988-06       Impact factor: 3.791

Review 4.  Use of Dried Blood Spot Specimens to Monitor Patients with Inherited Metabolic Disorders.

Authors:  Stuart J Moat; Roanna S George; Rachel S Carling
Journal:  Int J Neonatal Screen       Date:  2020-03-26

5.  Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers.

Authors:  Miguel Debono; Ashwini Mallappa; Verena Gounden; Aikaterini A Nella; Robert F Harrison; Christopher A Crutchfield; Peter S Backlund; Steven J Soldin; Richard J Ross; Deborah P Merke
Journal:  Eur J Endocrinol       Date:  2015-09-04       Impact factor: 6.664

6.  A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia.

Authors:  Ashwini Mallappa; Ninet Sinaii; Parag Kumar; Martin J Whitaker; Lori-Ann Daley; Dena Digweed; David J A Eckland; Carol Van Ryzin; Lynnette K Nieman; Wiebke Arlt; Richard J Ross; Deborah P Merke
Journal:  J Clin Endocrinol Metab       Date:  2014-12-11       Impact factor: 5.958

7.  An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia.

Authors:  Mahmoud Al-Kofahi; Mariam A Ahmed; Mutaz M Jaber; Thang N Tran; Brian A Willis; Cheryl L Zimmerman; Maria T Gonzalez-Bolanos; Richard C Brundage; Kyriakie Sarafoglou
Journal:  Br J Clin Pharmacol       Date:  2020-07-26       Impact factor: 3.716

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.